Medicine Experts

Gregory J. Flesher

Youdim Pharmaceuticals


  Mr. Flesher has served as the President, Chief Executive Officer and a member of the Board of Directors of Novus Therapeutics, Inc. since the acquisition of Otic Pharma, Ltd. by Novus Therapeutics (formerly Tokai Pharmaceuticals, Inc.) in May 2017.  Prior to the acquisition, Mr. Flesher served as Chief Executive Officer and a member of the Board of Directors for Otic Pharma, Ltd. from 2015 to 2017.  Mr. Flesher has over 20 years of pharmaceutical industry experience and has been closely involved with several successful drug development programs that have resulted in multiple product approvals and commercial launches in the U.S. and Europe.  Prior to Otic Pharma, Mr. Flesher served as Senior Vice President of Corporate Development and Chief Business Officer, and other executive management roles at Avanir Pharmaceuticals, Inc. from 2006 to 2015.  Mr. Flesher previously served in various sales, marketing, and clinical development roles at InterMune, Inc., Amgen, Inc., and Eli Lilly and Company from 1995 to 2006.  Mr. Flesher earned his Bachelor of Science in Biology from Purdue University and studied Biochemistry and Molecular Biology at Indiana University School of Medicine.

Research Interest

Pharmaceutical science 

Global Experts from Israel

Global Experts in Subject

Share This Profile
Recommended Conferences